The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Pediatric and adult patients experienced noninferior and robust immune responses to RIV4, as well as similar safety profiles.

A group of researchers from Japan's University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center said ...